Literature DB >> 23013167

Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology.

Robert W Mahley1, Yadong Huang.   

Abstract

An attractive strategy to treat proteinopathies (diseases caused by malformed or misfolded proteins) is to restore protein function by inducing proper three-dimensional structure. We hypothesized that this approach would be effective in reversing the detrimental effects of apolipoprotein (apo) E4, the major allele that significantly increases the risk of developing Alzheimer's disease and other neurodegenerative disorders. ApoE4's detrimental effects result from its altered protein conformation ("domain interaction"), making it highly susceptible to proteolytic cleavage and the generation of neurotoxic fragments. Here, we review apoE structure and function and how apoE4 causes neurotoxicity, and describe the identification of potent small-molecule-based "structure correctors" that induce proper apoE4 folding. SAR studies identified a series of small molecules that significantly reduced apoE4's neurotoxic effects in cultured neurons and a series that reduced apoE4 fragment levels in vivo, providing proof-of-concept for our approach. Structure-corrector-based therapies could prove to be highly effective for the treatment of many protein-misfolding diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23013167      PMCID: PMC4904786          DOI: 10.1021/jm3008618

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  111 in total

1.  APOE genotype is a major predictor of long-term progression of disability in MS.

Authors:  J Chapman; S Vinokurov; A Achiron; D M Karussis; K Mitosek-Szewczyk; M Birnbaum; D M Michaelson; A D Korczyn
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

2.  Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer.

Authors:  Qin Xu; Walter J Brecht; Karl H Weisgraber; Robert W Mahley; Yadong Huang
Journal:  J Biol Chem       Date:  2004-03-30       Impact factor: 5.157

3.  Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.

Authors:  Raquel L Lieberman; Brandon A Wustman; Pedro Huertas; Allan C Powe; Corey W Pine; Richie Khanna; Michael G Schlossmacher; Dagmar Ringe; Gregory A Petsko
Journal:  Nat Chem Biol       Date:  2006-12-24       Impact factor: 15.040

4.  The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.

Authors:  Richard A Steet; Stephen Chung; Brandon Wustman; Allan Powe; Hung Do; Stuart A Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

Review 5.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

6.  Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II.

Authors:  Toshika Okumiya; Marian A Kroos; Laura Van Vliet; Hiroaki Takeuchi; Ans T Van der Ploeg; Arnold J J Reuser
Journal:  Mol Genet Metab       Date:  2006-11-13       Impact factor: 4.797

7.  N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease.

Authors:  Hou Lin; Yuko Sugimoto; Yuki Ohsaki; Haruaki Ninomiya; Akira Oka; Miyako Taniguchi; Hiroyuki Ida; Yoshikatsu Eto; Seiichiro Ogawa; Yuji Matsuzaki; Miwa Sawa; Takehiko Inoue; Katsumi Higaki; Eiji Nanba; Kousaku Ohno; Yoshiyuki Suzuki
Journal:  Biochim Biophys Acta       Date:  2004-08-04

8.  Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.

Authors:  Adrian W R Serohijos; Tamás Hegedus; Andrei A Aleksandrov; Lihua He; Liying Cui; Nikolay V Dokholyan; John R Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-27       Impact factor: 11.205

9.  Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia.

Authors:  Federica Agosta; Keith A Vossel; Bruce L Miller; Raffaella Migliaccio; Stephen J Bonasera; Massimo Filippi; Adam L Boxer; Anna Karydas; Katherine L Possin; Maria Luisa Gorno-Tempini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-22       Impact factor: 11.205

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  50 in total

1.  Conformational analysis of apolipoprotein E3/E4 heteromerization.

Authors:  Kai-Han Tu; Devan Abhari; Vasanthy Narayanaswami
Journal:  FEBS J       Date:  2019-03-13       Impact factor: 5.542

2.  Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.

Authors:  Sylvia Villeneuve; William J Jagust
Journal:  J Prev Alzheimers Dis       Date:  2015-03

Review 3.  Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions.

Authors:  Aaron J Carman; Rennie Ferguson; Robert Cantu; R Dawn Comstock; Penny A Dacks; Steven T DeKosky; Sam Gandy; James Gilbert; Chad Gilliland; Gerard Gioia; Christopher Giza; Michael Greicius; Brian Hainline; Ronald L Hayes; James Hendrix; Barry Jordan; James Kovach; Rachel F Lane; Rebekah Mannix; Thomas Murray; Tad Seifert; Diana W Shineman; Eric Warren; Elisabeth Wilde; Huntington Willard; Howard M Fillit
Journal:  Nat Rev Neurol       Date:  2015-03-17       Impact factor: 42.937

4.  Alzheimer's disease: The forgetting gene.

Authors:  Laura Spinney
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

Review 5.  The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update.

Authors:  Laura Mahoney-Sanchez; Abdel Ali Belaidi; Ashley I Bush; Scott Ayton
Journal:  J Mol Neurosci       Date:  2016-09-19       Impact factor: 3.444

6.  Apolipoprotein E epsilon 4 allele is associated with ventricular expansion rate and surface morphology in dementia and normal aging.

Authors:  Florence F Roussotte; Boris A Gutman; Sarah K Madsen; John B Colby; Katherine L Narr; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2013-12-05       Impact factor: 4.673

Review 7.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 8.  Peripheral versus central nervous system APOE in Alzheimer's disease: Interplay across the blood-brain barrier.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Wenhui Qu; Ling Li
Journal:  Neurosci Lett       Date:  2019-06-07       Impact factor: 3.046

9.  Nuclear uptake of an amino-terminal fragment of apolipoprotein E4 promotes cell death and localizes within microglia of the Alzheimer's disease brain.

Authors:  Julia E Love; Ryan J Day; Justin W Gause; Raquel J Brown; Xinzhu Pu; Dustin I Theis; Chad A Caraway; Wayne W Poon; Abir A Rahman; Brad E Morrison; Troy T Rohn
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-04-15

Review 10.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.